Kits of hydralazine compounds and isosorbide dinitrate and/or isosorbide mononitrate

Abstract

The present invention provides methods of treating and preventing mortality associated with heart failure in an African American patient with hypertension and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, or a compound used to treat cardiovascular diseases. In the present invention, the hydralazine compound is preferably hydralazine or a pharmaceutically acceptable salt thereof. Preferred methods of the invention comprise administering hydralazine or a pharmaceutically acceptable salt thereof and isosorbide dinitrate.

Description

RELATED APPLICATIONS[0001]This application is continuation under 35 USC § 120 of U.S. application Ser. No. 10 / 210,113, filed Aug. 2, 2002, allowed, which is a continuation under 35 USC § 120 of U.S. application Ser. No. 09 / 658,261 filed Sep. 8, 2000, issued as U.S. Pat. No. 6,465,463, which claims priority under 35 USC § 119 to U.S. Application No. 60 / 171,102 filed Dec. 16, 1999, and to U.S. Application No. 60 / 152,616 filed Sep. 8, 1999.FIELD OF THE INVENTION[0002]The present invention provides methods of treating and preventing mortality associated with heart failure, improving oxygen consumption, quality of life and / or exercise tolerance in a black patient, with hypertension by administration of a therapeutically effective amount of at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, and / or...

AI Technical Summary

Benefits of technology

[0008]The present invention provides methods for treating and preventing mortality associated with heart failure, improving oxygen consumption, quality of life and / or exercise tolerance in non-Caucasian patients, preferably black patients, with hypertension by administering a therapeutically effective amount of at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, and / or a compound used to treat cardiovascular diseases. The hydralazine compound is preferably hydralazine, or a pharmaceutically acceptable salt thereof, such as hydralazine hydrochloride. The hydralazine compound and the isosorbide dinitrate or isosorbide mononitrate can be administered separately or as components of the same composition.

Problems solved by technology

Heart failure in black patients has been associated with a poorer prognosis than in white patients.

This syndrome is now the leading cause of hospitalization in individuals older than age 65 and is a major contributor to the escalation of heath care costs.

No data at present have examined whether similar differences exist between black patients and white patients with heart failure.

Images